Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · April 06, 2017

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (Onset 1)
Diabetes Care 2017 Mar 29;[EPub Ahead of Print], D Russell-Jones, BW Bode, C De Block, E Franek, SR Heller, C Mathieu, A Philis-Tsimikas, L Rose, VC Woo, AB Østerskov, T Graungaard, RM Bergenstal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading